CHCHD2P7

Across TCGA pan-cancer cohorts, CHCHD2P7 RNA is linked to patient survival in 14 of 34 cancer types, making it the most broadly survival-associated CHCHD2P7 data layer.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher CHCHD2P7 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated CHCHD2P7 expression acts as an unfavorable survival marker, although some lineages such as LUSC and KIRP show a favorable association.

STAD, CHOL, and ESCA are the cancer types where CHCHD2P7 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Tertile	II,III,IV	0.553	0.706	.003	93	view →
CHOL	DFS	Quartile	II,III,IV	0.096	0.557	.009	62	view →
ESCA	DFS	Median	All	0.232	0.430	.003	55	view →
LGG	DFS	Tertile	All	0.615	0.791	<.001	54	view →
LUSC	DFS	Quartile	All	0.511	0.338	<.001	41	view →
LUAD	DFS	Median	IV	0.212	0.777	.001	18	view →
TGCT	DFS	Tertile	All	0.615	0.844	.002	18	view →
LAML	DFS	Tertile	All	0.222	0.601	.004	18	view →
GBM	OS	Median	All	0.195	0.328	.002	11	view →
KIRP	DFS	Tertile	All	0.957	0.688	.044	8	view →
HNSC	DFS	Quartile	II,III,IV	0.493	0.725	.002	6	view →
COAD	DFS	Tertile	III,IV	0.721	0.386	.047	3	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 14 lineages.

CHCHD2P7–STAD (OS)

Open the STAD breakdown →